Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Ovulation induction in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in men with hypogonadotropic hypogonadism
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
The terminal elimination half-life ranges from 16 to 24 hours (mean ~19 hours) following subcutaneous administration. In patients with renal impairment, half-life may be prolonged, necessitating dose adjustment.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Follitropin beta is metabolized primarily in the liver and kidneys via proteolytic degradation; no specific cytochrome P450 involvement.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal; approximately 70% of the dose is excreted unchanged in urine. A minor fraction (less than 5%) appears in feces via biliary elimination. The remainder is metabolized via hepatic pathways to inactive metabolites.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 45-50% bound, primarily to albumin and to a lesser extent to alpha-2-macroglobulin.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.3 L/kg (range 0.2-0.4 L/kg), consistent with distribution largely into extracellular fluid.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Subcutaneous: Approximately 77% (compared to intravenous administration). Intramuscular: approximately 75%. Not available for other routes.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific guidelines; use caution in severe impairment (e GFR <30 m L/min/1.73m²) due to limited data.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C) due to limited data.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not FDA-approved for pediatric use; off-label doses: 75-150 IU subcutaneously daily, weight-based titration (1.5-2.25 IU/kg/day) for adolescent males with hypogonadotropic hypogonadism.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for geriatric use; no dose adjustment recommended, but limited data in elderly >65 years.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
Follistim should be used only by physicians experienced in infertility treatment. It may cause ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Serious pulmonary and vascular events have been reported.
None.
Ovarian hyperstimulation syndrome (OHSS) can be severe; monitor ovarian response. Risk of multiple gestation and ectopic pregnancy. Ovarian torsion and adnexal torsion reported. Thromboembolic events. Ovarian enlargement may occur. Patients with porphyria may exacerbate condition.
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Hypersensitivity to follitropin beta or any component. High levels of FSH indicating primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Ovarian cyst or enlargement unrelated to PCOS. Pregnancy. Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary). Abnormal genital bleeding of undetermined origin.
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No specific food interactions are documented. Grapefruit and grapefruit juice may potentially affect hormone metabolism, though not established for Follistim; advise patients to maintain a consistent diet and report unusual changes.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and use is contraindicated in pregnant women. In the first trimester, exposure may cause fetal harm; however, no well-controlled studies exist. The drug is not used after conception, as its sole indication is for ovulation induction and controlled ovarian stimulation prior to assisted reproductive technologies.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
FOLLISTIM is not recommended for use during breastfeeding. It is not known whether follitropin beta is excreted in human milk. Given the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
There are no recommended dosing adjustments for FOLLISTIM during pregnancy because the drug is contraindicated and not used in pregnancy. Pregnancy results from treatment, at which point FOLLISTIM is discontinued. No pharmacokinetic changes are studied in pregnancy as it is not administered to pregnant women.
Do not use in pregnancy. No dose recommendations available; contraindicated.
Follistim (follitropin beta) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing. Risk of ovarian hyperstimulation syndrome (OHSS) increases with high estradiol (>3000 pg/m L) and multiple follicles. Do not use in primary ovarian failure, uncontrolled thyroid/adrenal disorders, or sex hormone-dependent tumors. For subcutaneous administration; rotate injection sites.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Follistim is injected subcutaneously exactly as prescribed; do not skip or change dose without talking to your doctor.,You will need regular blood tests and ultrasounds to monitor your response and adjust treatment.,Common side effects include injection site reactions, headache, nausea, and bloating.,Contact your doctor immediately if you experience severe pelvic pain, sudden weight gain, or difficulty breathing, which could indicate ovarian hyperstimulation syndrome (OHSS).,Follistim increases the chance of multiple pregnancy (twins, triplets).,Store vials in the refrigerator, not frozen, and protect from light. Do not use if solution is cloudy or contains particles.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM vs ANDEMBRY, answered by our medical review team.
FOLLISTIM is a Gonadotropin that works by Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM is: Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM is classified as Category C. FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and . ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.